Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound

Trial Profile

Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Low HDL cholesterol
  • Focus Therapeutic Use
  • Acronyms ASSURE; ASSURE-1
  • Sponsors Resverlogix Corporation
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 May 2017 According to a Resverlogix Corporation media release, results from the post-hoc analysis of SUSTAIN and ASSURE trials will be presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress 2017.
    • 16 Nov 2016 Results of post hoc analysis of phase IIb ASSERT and ASSURE trials (n=51), presented at the 89th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top